Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioannis Zerdes

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|March 26, 2025
Response to Yuan and YuIoannis Zerdes, Antonios Valachis
Molecular Oncology|March 9, 2023
The interplay between eosinophils and T cells in breast cancer immunotherapyIoannis Zerdes, Alexios Matikas, Theodoros Foukakis
Drug Discovery Today|November 25, 2024
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236Panagiotis Filis, Dimitrios Salgkamis, Alexios Matikas, et al.
Breast Cancer Research and Treatment|July 1, 2023
Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysisJustus Rosin, Ella Svegrup, Antonios Valachis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2026
Empowering the next generation of clinical cancer researchers: Structure, activities, and vision of the European Organisation for Research and Treatment of Cancer (EORTC) Young and Early Career Investigator (Y-ECI) networkIoannis Zerdes, Jens Lehmann, Christine Olungu, et al.
Cancers|May 8, 2019
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer ImmunotherapySebastian Chrétien, Ioannis Zerdes, Jonas Bergh, et al.
Critical Reviews in Oncology/Hematology|October 22, 2023
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic reviewPanagiotis Filis, Ioannis Zerdes, Theodora Soumala, et al.
Future Oncology (London, England)|March 19, 2016
Palbociclib: an approval at last for HER2-negative breast cancerIoannis Zerdes, Demosthenes E Ziogas, Efstathios G Lykoudis, et al.
Oncogene|May 17, 2018
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlationsIoannis Zerdes, Alexios Matikas, Jonas Bergh, et al.
Anticancer Research|November 1, 2016
Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological MalignanciesStergios Boussios, George Zarkavelis, Esmeralda Seraj, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|March 26, 2025
Response to Yuan and YuIoannis Zerdes, Antonios Valachis
Molecular Oncology|March 9, 2023
The interplay between eosinophils and T cells in breast cancer immunotherapyIoannis Zerdes, Alexios Matikas, Theodoros Foukakis
Drug Discovery Today|November 25, 2024
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236Panagiotis Filis, Dimitrios Salgkamis, Alexios Matikas, et al.
Breast Cancer Research and Treatment|July 1, 2023
Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysisJustus Rosin, Ella Svegrup, Antonios Valachis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2026
Empowering the next generation of clinical cancer researchers: Structure, activities, and vision of the European Organisation for Research and Treatment of Cancer (EORTC) Young and Early Career Investigator (Y-ECI) networkIoannis Zerdes, Jens Lehmann, Christine Olungu, et al.
Cancers|May 8, 2019
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer ImmunotherapySebastian Chrétien, Ioannis Zerdes, Jonas Bergh, et al.
Critical Reviews in Oncology/Hematology|October 22, 2023
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic reviewPanagiotis Filis, Ioannis Zerdes, Theodora Soumala, et al.
Future Oncology (London, England)|March 19, 2016
Palbociclib: an approval at last for HER2-negative breast cancerIoannis Zerdes, Demosthenes E Ziogas, Efstathios G Lykoudis, et al.
Oncogene|May 17, 2018
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlationsIoannis Zerdes, Alexios Matikas, Jonas Bergh, et al.
Anticancer Research|November 1, 2016
Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological MalignanciesStergios Boussios, George Zarkavelis, Esmeralda Seraj, et al.
Pageof 6